You can buy or sell ABEO and other stocks, options, ETFs, and crypto commission-free!
Abeona Therapeutics Inc. Common Stock, also called Abeona Therapeutics, is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. Read More It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Seeking AlphaMay 14
Abeona Therapeutics Inc. CEO João Siffert on Q1 2019 Results - Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q1 2019 Earnings Conference Call May 14, 2019 10:00 AM ET Company Participants Sofia Warner - Senior Director, Investor Relations João Siffert - Chief Executive Officer, Head of Research & Development and Chief Medical Officer Timothy Miller - President and Chief Scientific Officer Christine Berni-Silverstein - Chief Financial Officer Conference Call Participants David Steinberg - Jefferies & Company, Inc. Liav Abraham - Citigroup Edward Marks - H.C. Wainwrigh...
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
NEW YORK and CLEVELAND, May 07, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the following upcoming investor conferences. SunTrust Robinson Humphrey 5th Annual Life Science Summit One-on-one Meetings May 8, 2019 Lotte New York Palace, New York, NY 2019 RBC Capital Markets Healthcare Conference Fireside Chat May 22, 2019, 1:35 p.m. ET The InterContinental New York Barclay Hotel, New York...
-$0.32 per share
-$0.39 per share